Link
With the growth of parallel trade of pharmaceuticals in the European Union increasing consistently (despite numerous challenges from some of the industry’s biggest players) this event is more relevant than ever. The principles of free movement of goods and the regional exhaustion of intellectual property rights, as well as the European Court of Justice consistently ruling in their favour on cases relating to trademark issues have led to great financial success for parallel traders. In response, pharmaceutical companies are now looking towards new solutions and strategies to address parallel trade, leading case studies of which will be discussed and presented at the 2012 conference.